Novartis sees new model in BioE deal
This article was originally published in Scrip
Executive Summary
Novartis has signed a deal for typhoid vaccines with Indian firm Biological-E which it hopes will form the basis for a new, more effective model to get products for neglected diseases to people in poor countries. According to Don Ganem, vice-president and global head of infectious diseases at the Novartis Institutes for BioMedical Research, it represents "a prototype for how we would like to operate in the area of neglected diseases: not just vaccines, but also drugs."